Celadon Pharmaceuticals Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CEL.L research report →
Companywww.celadonpharma.co.uk
Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis.
- CEO
- James Gareth Short
- IPO
- 2022
- Employees
- 27
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $9.23M
- P/E
- -1.16
- P/S
- 123.00
- P/B
- 2.63
- EV/EBITDA
- -1.98
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 1.33%
- Op Margin
- -7908.00%
- Net Margin
- -9520.00%
- ROE
- -131.82%
- ROIC
- -68.65%
Growth & Income
- Revenue
- $75.00K · 212.50%
- Net Income
- $-7,140,000 · 58.99%
- EPS
- $-0.12 · 60.00%
- Op Income
- $-5,931,000
- FCF YoY
- 22.88%
Performance & Tape
- 52W High
- $83.00
- 52W Low
- $0.06
- 50D MA
- $7.86
- 200D MA
- $16.42
- Beta
- 0.19
- Avg Volume
- 182.29K
Get TickerSpark's AI analysis on CEL.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CEL.L Coverage
We haven't published any research on CEL.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CEL.L Report →